Scryb Grants Stock Options

Scryb Inc. (CSE: SCYB,OTC:SCYRF) (OTC Pink: SCYRF) (FSE: EIY) ("Scryb'' or the "Company") announces that it has granted 3,870,000 stock options (the "Options") to various employees, directors, officers and consultants of the Company.

Each Option is exercisable at a price of $0.12 for one common share of the Company (each a "Common Share") for a period of five years from the date of grant and are being issued under the terms of the Company's Omnibus Long-Term Incentive Plan. The Options, and any Common Shares issued upon exercise of the Options, are subject to a four-month and one day resale restriction from the date of grant under applicable securities laws and the policies of the Canadian Securities Exchange (the "CSE").

The aforementioned grant of Options resulted in certain directors and officers of the Company receiving an aggregate of 2,910,000 Stock Options. The Company has relied on the exemptions from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"), contained in section 5.5(b) and 5.7(a) of MI 61-101 in respect of such insider participation.

About Scryb
Scryb invests in and actively supports a growing portfolio of innovative and high-upside ventures across the technology sector.

Contact:
James Van Staveren, CEO
Phone: 647-847-5543
Email: info@scryb.ai

Forward-Looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to, delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. There are no assurances that the commercialization plans for the technology described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at https://www.sedarplus.ca/.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268654

News Provided by Newsfile via QuoteMedia

SCYB:CC
The Conversation (0)
Sona Nanotech To Hold Investor Webinar To Discuss Follow-up Data From First-in-human Cancer Therapy Study

Sona Nanotech To Hold Investor Webinar To Discuss Follow-up Data From First-in-human Cancer Therapy Study

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/Sona Nanotech Inc. (CSE: SONA,OTC:SNANF) (OTCQB: SNANF) (the "Company", "Sona"), will host an investor webinar on Wednesday, March 18th at 3:30pm ET to discuss follow-up data from its... Keep Reading...
Half Yearly Report and Accounts

Half Yearly Report and Accounts

RocketBoots (ROC:AU) has announced Half Yearly Report and AccountsDownload the PDF here. Keep Reading...
31 December 2025 Appendix 4D and Interim Financial Report

31 December 2025 Appendix 4D and Interim Financial Report

RemSense Technologies (REM:AU) has announced 31 December 2025 Appendix 4D and Interim Financial ReportDownload the PDF here. Keep Reading...
Mockup of person with brain chip like the one Neuralink is creating.

Can You Invest in Neuralink?

Elon Musk's Neuralink has captured the public’s attention and imagination with its futuristic vision of connecting the human brain to computers.Neuralink has drawn interest to the brain computer interface (BCI) sector with its N1 implant, which is undergoing human trials in patients with spinal... Keep Reading...
Laptop with overlay of fluctuating financial graphs and data points.

Tech Weekly: Mega-cap Earnings Dominate Narrow Trading Week

Welcome to the Investing News Network's weekly brief on tech news and tech stocks driving the market. We also break down next week's catalysts to watch to help you prepare for the week ahead.Don't forget to follow us @INN_Technology for real-time news updates!Securities Disclosure: I, Meagen... Keep Reading...
Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

RocketBoots (ROC:AU) has announced Quarterly Activities/Appendix 4C Cash Flow ReportDownload the PDF here. Keep Reading...

Interactive Chart

Latest Press Releases

Related News